Deutsche Bank AG Sells 3,685 Shares of SiBone $SIBN

Deutsche Bank AG cut its holdings in shares of SiBone (NASDAQ:SIBN) by 10.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,583 shares of the company’s stock after selling 3,685 shares during the quarter. Deutsche Bank AG owned 0.08% of SiBone worth $457,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in SIBN. Silvercrest Asset Management Group LLC increased its holdings in shares of SiBone by 21.9% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company’s stock worth $27,392,000 after purchasing an additional 350,970 shares during the period. Victory Capital Management Inc. increased its holdings in shares of SiBone by 55.0% during the first quarter. Victory Capital Management Inc. now owns 631,568 shares of the company’s stock worth $8,861,000 after buying an additional 224,190 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of SiBone by 17.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,263,988 shares of the company’s stock worth $17,721,000 after buying an additional 190,830 shares in the last quarter. Lisanti Capital Growth LLC acquired a new position in shares of SiBone during the first quarter worth $2,364,000. Finally, Raymond James Financial Inc. acquired a new position in shares of SiBone during the fourth quarter worth $1,233,000. 98.11% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Jeffrey W. Dunn sold 3,377 shares of the business’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $19.05, for a total value of $64,331.85. Following the transaction, the director owned 17,354 shares in the company, valued at $330,593.70. The trade was a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Laura Francis sold 11,343 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $15.60, for a total transaction of $176,950.80. Following the transaction, the chief executive officer owned 419,704 shares in the company, valued at $6,547,382.40. This represents a 2.63% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,967 shares of company stock valued at $829,469 over the last quarter. Company insiders own 4.00% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on SIBN shares. Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Truist Financial upped their price target on shares of SiBone from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, May 6th. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $24.00 price target on shares of SiBone in a report on Tuesday, May 6th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $23.67.

SiBone Price Performance

SIBN stock opened at $16.59 on Thursday. The firm has a market cap of $715.69 million, a price-to-earnings ratio of -29.62 and a beta of 0.91. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21. SiBone has a 12-month low of $11.70 and a 12-month high of $20.05. The company’s fifty day simple moving average is $17.01 and its 200 day simple moving average is $16.51.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. The business had revenue of $48.63 million for the quarter, compared to analyst estimates of $48.12 million. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. SiBone has set its FY 2025 guidance at EPS. On average, analysts expect that SiBone will post -0.78 earnings per share for the current year.

SiBone Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.